UB Paderborn / Katalog / Suche / in CDI

1 – 17 von 17

Sortiert nach

Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer

The American journal of pathology, 2011-03, Vol.178 (3), p.989-996

2011

Link zum Volltext

Verfügbarkeit prüfen

Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma

Journal of investigative dermatology, 2013-06, Vol.133 (6), p.1582-1590

2013

Link zum Volltext

Verfügbarkeit prüfen

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Nature communications, 2023-07, Vol.14 (1), p.4444-4444, Article 4444

2023

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Nature communications, 2023-08, Vol.14 (1), p.4741-4741, Article 4741

2023

Link zum Volltext

Verfügbarkeit prüfen

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5213-5224

2021

Link zum Volltext

Verfügbarkeit prüfen

The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers

Cancer chemotherapy and pharmacology, 2008-01, Vol.61 (1), p.23-32

2008

Link zum Volltext

Verfügbarkeit prüfen

Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement

British journal of cancer, 2020-02, Vol.122 (4), p.473-482

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract PS13-05: A phase 2 study of oral paclitaxel and encequidar (oPac+E) in the treatment of cutnaeous angiosarcoma: The breast angiosarcoma subgroup

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS13-05-PS13-05

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-10

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS3-10-GS3-10

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4791-4791

2018

Link zum Volltext

Verfügbarkeit prüfen

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

The Journal of molecular diagnostics : JMD, 2014-05, Vol.16 (3), p.343-349

2014

Link zum Volltext

Verfügbarkeit prüfen

Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data

BMC cancer, 2016-08, Vol.16 (1), p.703-703, Article 703

2016

Link zum Volltext

Verfügbarkeit prüfen

Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women

European journal of cancer (1990), 2007-11, Vol.43 (17), p.2523-2531

2007

Link zum Volltext

Verfügbarkeit prüfen

Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study

Bone (New York, N.Y.), 2012-04, Vol.50 (4), p.885-892

2012

Link zum Volltext

Verfügbarkeit prüfen

Translational modelling of preclinical cardiovascular findings to patients

Journal of pharmacological and toxicological methods, 2014-11, Vol.70 (3), p.326-327

2014

Link zum Volltext

Verfügbarkeit prüfen

Tissue collection in drug discovery and development research

European journal of cancer supplements, 2007-12, Vol.5 (9), p.33-36

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 17 von 17

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(17)

Sprache

Englisch
(17)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Humans
(10)
Life Sciences & Biomedicine
(10)
Oncology
(6)
Female
(5)
Male
(5)
Middle Aged
(5)
Aged
(4)
Biological And Medical Sciences
(4)
Medical Sciences
(4)
Biomarkers, Tumor - Metabolism
(3)
Clinical Trials
(3)
Tumors
(3)
Adult
(2)
Aged, 80 And Over
(2)
Biopsy
(2)
Bone Remodeling - Drug Effects
(2)
Cancer Research
(2)
Dose-Response Relationship, Drug
(2)
Hematology, Oncology And Palliative Medicine
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer

Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers

Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement

Abstract PS13-05: A phase 2 study of oral paclitaxel and encequidar (oPac+E) in the treatment of cutnaeous angiosarcoma: The breast angiosarcoma subgroup

Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data

Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women

Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study

Translational modelling of preclinical cardiovascular findings to patients

Tissue collection in drug discovery and development research

Aktive Filter

Suchergebnisse filtern